Prof. Tieqiao Chen

Hainan University, China

Bio: Tieqiao Chen holds a B.S., M.S., and Ph.D. in Chemistry from Hunan University and is a member of the Chinese Communist Party. He is currently a Category C high-level talent, Professor, and Doctoral Supervisor at Hainan University, where he serves as Director of the Green and Precision Synthesis Research Center. Concurrently, he holds the positions of Chief Technology Officer for APIs at Venture Pharma (Hainan) Co., Ltd. and Director of the Hainan Provincial Small Molecule Drug Manufacturing Innovation Center (in cultivation).

He serves as the Academic Editor for the international SCI journal Heteroatom Chemistry and as an editorial board member for National Journal of Molecular Sciences and Chinese Chemical Letters. His long-term research focuses on functional molecular design and synthesis, specializing in the activation and transformation of carboxylic acids and their derivatives, green synthesis of organophosphorus compounds. He has published over 110 papers as first or corresponding author in prestigious international journals such as J. Am. Chem. Soc. (4 papers, including a 2018 paper that was the first from a Hainan institution as the first unit), Angew. Chem. Int. Ed. (2 papers), and Nat. Commun. (1 paper). His work has been cited over 4,300 times with an H-index of 36. He has contributed one chapter each to Wiley and Thieme’s book. He has led 3 National Natural Science Foundation projects and 4 provincial/ministerial-level projects.

In industrial translation, he has overseen the development of more than 10 generic drugs including vortioxetine, brexpiprazole, and itraconazole. Among these, vortioxetine and brexpiprazole have completed production verification, with registration materials currently being prepared. He led a cost-reduction and efficiency-improvement project for loratadine API, reducing the cost per kilogram by approximately 500 CNY, achieving annual savings of 4 million CNY and significant economic benefits. He also developed a novel process for loratadine, creating a new synthetic route for the key intermediate methyl-loratadine, thereby breaking a long-standing “bottleneck” dependence on imports from India. This project is set to enter pilot-scale testing.